156 related articles for article (PubMed ID: 23835189)
1. Effect of therapeutic arsenic exposure on pulmonary function.
Ho JC; Au WY; Han L; Kwong YL; Ip MS
Respir Med; 2013 Sep; 107(9):1423-30. PubMed ID: 23835189
[TBL] [Abstract][Full Text] [Related]
2. Age-associated changes in pulmonary function: a comparison of pulmonary function parameters in healthy young adults and the elderly living in Shanghai.
Ren WY; Li L; Zhao RY; Zhu L
Chin Med J (Engl); 2012 Sep; 125(17):3064-8. PubMed ID: 22932182
[TBL] [Abstract][Full Text] [Related]
3. Dose-adjusted arsenic trioxide for acute promyelocytic leukaemia in chronic renal failure.
Firkin F; Roncolato F; Ho WK
Eur J Haematol; 2015 Oct; 95(4):331-5. PubMed ID: 25600167
[TBL] [Abstract][Full Text] [Related]
4. Forced vital capacity and forced expiratory volume in six seconds as predictors of reduced total lung capacity.
Vandevoorde J; Verbanck S; Schuermans D; Broekaert L; Devroey D; Kartounian J; Vincken W
Eur Respir J; 2008 Feb; 31(2):391-5. PubMed ID: 17928313
[TBL] [Abstract][Full Text] [Related]
5. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial.
Zhu HH; Wu DP; Jin J; Li JY; Ma J; Wang JX; Jiang H; Chen SJ; Huang XJ
J Clin Oncol; 2013 Nov; 31(33):4215-21. PubMed ID: 24127444
[TBL] [Abstract][Full Text] [Related]
6. Kurtosis and skewness of density histograms on inspiratory and expiratory CT scans in smokers.
Yamashiro T; Matsuoka S; Estépar RS; Bartholmai BJ; Diaz A; Ross JC; Murayama S; Silverman EK; Hatabu H; Washko GR
COPD; 2011 Feb; 8(1):13-20. PubMed ID: 21299474
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of pulmonary function in patients treated with paclitaxel and carboplatin.
Dimopoulou I; Galani H; Dafni U; Samakovii A; Roussos C; Dimopoulos MA
Cancer; 2002 Jan; 94(2):452-8. PubMed ID: 11900231
[TBL] [Abstract][Full Text] [Related]
8. Lung function outcome at school age in very low birth weight children.
Cazzato S; Ridolfi L; Bernardi F; Faldella G; Bertelli L
Pediatr Pulmonol; 2013 Aug; 48(8):830-7. PubMed ID: 23129340
[TBL] [Abstract][Full Text] [Related]
9. [Changes in pulmonary function in SARS patients during the three-year convalescent period].
Liu YX; Ye YP; Zhang P; Chen J; Ye H; He YH; Li N
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2007 Sep; 19(9):536-8. PubMed ID: 17767822
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide inhibits metastatic potential of mouse hepatoma H22 cells in vitro and in vivo.
Zhao XS; Song PL; Sun B; Jiang HC; Liu TF
Hepatobiliary Pancreat Dis Int; 2009 Oct; 8(5):510-7. PubMed ID: 19822495
[TBL] [Abstract][Full Text] [Related]
11. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
12. Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment.
Au WY; Tam S; Kwong YL
Leuk Res; 2008 Feb; 32(2):357-8. PubMed ID: 17662385
[No Abstract] [Full Text] [Related]
13. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia.
Lengfelder E; Hofmann WK; Nowak D
Leukemia; 2012 Mar; 26(3):433-42. PubMed ID: 21904379
[TBL] [Abstract][Full Text] [Related]
14. Non-lethal bone marrow necrosis under first-line arsenic trioxide therapy in acute promyelocytic leukaemia.
Ianotto JC; Tempescul A; Eveillard JR; Charles F; Berthou C
Acta Haematol; 2010; 123(3):146-7. PubMed ID: 20134156
[No Abstract] [Full Text] [Related]
15. Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia.
Zhang Y; Zhang Z; Li J; Li L; Han X; Han L; Hu L; Wang S; Zhao Y; Li X; Zhang Y; Fan S; Lv C; Li Y; Su Y; Zhao H; Zhang X; Zhou J
Cancer; 2013 Jan; 119(1):115-25. PubMed ID: 22930197
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F; Avvisati G; Vignetti M; Thiede C; Orlando SM; Iacobelli S; Ferrara F; Fazi P; Cicconi L; Di Bona E; Specchia G; Sica S; Divona M; Levis A; Fiedler W; Cerqui E; Breccia M; Fioritoni G; Salih HR; Cazzola M; Melillo L; Carella AM; Brandts CH; Morra E; von Lilienfeld-Toal M; Hertenstein B; Wattad M; Lübbert M; Hänel M; Schmitz N; Link H; Kropp MG; Rambaldi A; La Nasa G; Luppi M; Ciceri F; Finizio O; Venditti A; Fabbiano F; Döhner K; Sauer M; Ganser A; Amadori S; Mandelli F; Döhner H; Ehninger G; Schlenk RF; Platzbecker U; ; ;
N Engl J Med; 2013 Jul; 369(2):111-21. PubMed ID: 23841729
[TBL] [Abstract][Full Text] [Related]
17. Lung function in children with diabetes mellitus.
Cazzato S; Bernardi F; Salardi S; Tassinari D; Corsini I; Ragni L; Cicognani A; Cacciari E
Pediatr Pulmonol; 2004 Jan; 37(1):17-23. PubMed ID: 14679484
[TBL] [Abstract][Full Text] [Related]
18. Herpes zoster during treatment with arsenic trioxide.
Tanvetyanon T; Nand S
Ann Hematol; 2004 Mar; 83(3):198-200. PubMed ID: 15064871
[TBL] [Abstract][Full Text] [Related]
19. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
20. Impairment of heart rate variability control during arsenic trioxide treatment for acute promyelocytic leukemia.
Takeshita A; Uehara A; Shinjo K; Naito K; Sahara N; Yamazaki K; Katoh H; Kamikawa T; Ohnishi K; Maekawa M; Hayashi H; Ohno R
Leukemia; 2004 Mar; 18(3):647-8. PubMed ID: 14671633
[No Abstract] [Full Text] [Related]
[Next] [New Search]
